Trisalus Life Sciences, Inc. · NASDAQ:TLSI

Trisalus Life Sciences — Investor Presentation (September 2023)

28 slides from Trisalus Life Sciences's investor presentation, Sep 1, 2023

  1. Slide 1: TriSalus Life Sciences – September 2023

    1 OUR MISSION : TriSalus Life Sciences seeks to Transform the way liver and pancreatic tumors are treated through our immunotherapeutic and drug delivery technology TriSalus Life Sciences SEPTEMBER 2023

  2. Slide 2: Disclaimer

    Disclaimer © 2023 TriSalus Œ Life Sciences. All Rights Reserved. 2 Certain statements in this presentation may constitute “forward looking statements” within the meaning of applicable United S tat es federal securities laws. Forward looking statements include, but are not limited to, statements rega

  3. Slide 3: Well-Positioned to Create Value by Improving Outcomes for Patients with Liver and Pancreatic Tumors

    3 Well - Positioned to Create Value by Improving Outcomes for Patients with Liver and Pancreatic Tumors Fast - growing, commercial Medtech business with potential upside from promising immunotherapeutic combination Multiple value - creating opportunities (sales growth and new product launches, thera

  4. Slide 4: Our Company is Focused on Areas of Greatest Unmet Need

    4 Our Company is Focused on Areas of Greatest Unmet Need Novel Combination Approach combines innovative Pressure Enabled Drug Delivery Π(PEDD) delivery technology with a promising therapeutic, SD - 101, TLR9 agonist Uveal Melanoma Liver Metastases 5 - year survival 16% 1 Hepatocellular Carcinoma Ch

  5. Slide 5: TriNav: A Better Solution for Drug Delivery

    5 TriNav: A Better Solution for Drug Delivery TriNav Commercial - stage FDA cleared technology using the proprietary PEDD approach 2022 $12.4M Sales 82% GM 2023E $19.0M Sales 84% GM 2021 $8.4M Sales 79% GM Drug delivery technology to overcome the barriers of the high - pressure tumor microenvironmen

  6. Slide 6: Our Drug Delivery Technology

    6 Our Drug Delivery Technology

  7. Slide 7: The Problem We Are Solving

    7 The Problem We Are Solving… < 1 % of the IV dose ends up in solid tumors 7

  8. Slide 8: High Intratumoral Pressure Within the Tumor Limits Drug Uptake

    8 High Intratumoral Pressure Within the Tumor Limits Drug Uptake Necrosis Limited drug uptake due to collapsed vessels The pressure within the tumor can be higher than the patient’s blood pressure, limiting drug uptake

  9. Slide 9: TriSalus' PEDD Approach Works in Sync with the Cardiac Cycle

    9 TriSalus ’ PEDD Approach Works in Sync with the Cardiac Cycle to Modulate Pressure and Flow to Overcome These Barriers Work in sync with the cardiac cycle 1* A traumatically increase local vascular pressure at the target location close to the tumor 2 ‡ Infuse therapeutics into resistive tumor vess

  10. Slide 10: PEDD Procedures are Routine Interventional Radiology Liver Procedures

    10 PEDD Procedures are Routine Interventional Radiology Liver Procedures Done in an Outpatient Setting 3 2 1 Enhanced pressure and flow maximize dose to tumor 3 X - rays are used to guide a catheter to the site of the lesion 2 A small puncture is made, usually into the femoral artery near the groin

  11. Slide 11: Enhanced Delivery Pressure to Improve Therapeutic Penetration

    11 Enhanced Delivery Pressure to Improve Therapeutic Penetration Conceptual. For illustrative purposes STANDARD CATHETER PEDD Pressure Enabled Drug Delivery Drug flows around tumor limiting therapeutic effectiveness Collapsed vessels opened for deep perfusion throughout vasculature of the tumor

  12. Slide 12: PEDD Drives More Therapeutic Into High Pressure Tumors

    12 PEDD Drives More Therapeutic Into High Pressure Tumors 1 Angiogram of tumor vessels demonstrating that PEDD: Interventional radiologist injected contrast dye into tumor vessels. Same liver cancer patient treated with different devices. Surefire increases pressure during infusion, overcoming tumor

  13. Slide 13: PEDD Increases Delivery of Multiple Therapeutics Versus Standard Technology

    13 PEDD Increases Delivery of Multiple Therapeutics Versus Standard Technology Therapeutic Modality TriNav Improvement vs. Standard Catheter TACE 60% ↑ in therapeutic delivery to liver tumors 1 vs. standard catheter Clinical Study TARE (Y - 90) 33% - 90% ↑ in MAA deposition in liver tumors 2 vs. sta

  14. Slide 14: FDA Cleared Novel Pancreas Infusion System

    14 • Poor blood flow limits drug access to the pancreas 1 - 3 • Pancreatic arteries difficult to access 4,5 • Innovative retrograde venous approach eliminates need for balloons 6,7 • Leveraging PEDD and SD - 101 experience from liver trials to • Phase 1 locally advanced pancreas data from MDACC to b

  15. Slide 15: TriSalus Technology Pipeline

    15 TriSalus Technology Pipeline 15 Currently in Phase 1 clinical trials with SD - 101 TriNav 510k Cleared Pancreatic Infusion 510k Cleared Large Vessel TriNav 510k Cleared Launch Planned 1H: 2024 TriNav receives Transitional Passthrough Payment Small Vessel TriNav In Development Focused on <1.5mm ve

  16. Slide 16: Significant Potential Upside from SD-101, a TLR9 agonist, in Clinical Development

    16 Significant Potential Upside from SD - 101, a TLR9 agonist, in Clinical Development

  17. Slide 17: SD-101: U.S. Addressable Market Across Indications > $15B

    17 SD - 101: U.S. Addressable Market Across Indications > $15B • Addressing unresectable disease in liver and pancreas • Target indications all areas of high unmet need with poor overall survival • Addressable population >80,000 1 in the U.S. • High global incidence in key targeted indications provi

  18. Slide 18: SD-101 via PEDD Leads to Systemic Immune Effect

    18 Unresponsive “cold” Tumor Pre - SD - 101 TriSalus PEDD + SD - 101 Responsive “hot” Tumor Post - SD - 101 SD - 101 via PEDD Leads to Systemic Immune Effect MDSC accumulation, T cell paucity, and immunotherapy failure PEDD unlocks dual mechanism of action in liver and pancreas Systemic immune stimu

  19. Slide 19: SD-101 Dual Mechanism of Action Chosen for Liver and Pancreas

    19 1. SD - 101 binds to TLR9 SD - 101 Dual Mechanism of Action Chosen for Liver and Pancreas MDSC SD - 101 Endothelial cell NK pDC 3. MDSC elimination 2 . Broad TME activation by SD - 101 via PEDD 4. T cells accumulate in tumor for CPI binding SD - 101 acts on multiple cell types Dual mechanism of a

  20. Slide 20: Pipeline Designed to Enable Immunotherapy in Liver and Pancreas Tumors

    20 Pipeline Designed to Enable Immunotherapy in Liver and Pancreas Tumors INDICATION TRIAL DESIGN IND ENABLING PHASE 1 PHASE 2 PHASE 3 ANTICIPATED MILESTONES Uveal Melanoma Liver Metastases (Validation of combination) SD - 101 + PEDD HAI + CPI • 2H 2023: Phase 1 data • 2H 2023: Initiate Phase 2 tria

  21. Slide 21: Studies Run by Internationally Renowned Cancer Centers

    21 Studies Run by Internationally Renowned Cancer Centers

  22. Slide 22: SD-101: Longer than expected survival times in metastatic uveal melanoma with liver metastases

    22 SD - 101: Longer than expected survival times in metastatic uveal melanoma with liver metastases 21% ctDNA clearance 1 vs (13% with tebentafusp 2 ) in pre - treated patients ctDNA Reported as predictor of overall survival in stage IV uveal melanoma 2 Lines of Prior Treatment* N 0 5 1 12 2 4 3 2 5

  23. Slide 23: SD-101 Well Tolerated with Low Level of Serious AEs

    23 SD - 101 Well Tolerated with Low Level of Serious AE’s PEDD concentrates SD - 101 in liver with well - tolerated systemic immune effects TS - PERIO - 01 Phase 1 (1L if Kimmtrak ineligible; 2L+ if Kimmtrak eligible) TriSalus (SD - 101) N=39 (phase 1) Immunocore (Kimmtrak) N=378 (2:1 RCT) Ideaya (P

  24. Slide 24: 2023–2024: Anticipated Key Milestones

    24 2023 – 2024: Anticipated Key Milestones Catalyst Indication Anticipated Timing Phase 1 PERIO Data Uveal Melanoma 2H 2023 Initiation of Phase 2 Uveal Melanoma 1H 2024 Launch of TriNav Large Hepatocellular Cancer 1H 2024 Initiation of Phase 1 Y - 90 + SD - 101 Hepatocellular Cancer 1H 2024 Phase 1

  25. Slide 25: Executive Team and Board of Directors

    25 Executive Team Mats Wahlstrom Chairman Steven Katz, MD, FACS Chief Medical Officer, Chairman of SAB Sean Murphy Chief Financial Officer Jennifer Stevens Chief Regulatory Officer Bryan Cox, PHD Chief of Research Jim Alecxih President, Device Technology Mary Szela CEO & President Richard Marshak VM

  26. Slide 26: Capital Structure and Share Information as of August 31, 2023

    26 Capital Structure and Share Information as of August 31, 2023 Share Listing – Current TLSI (Nasdaq) Common Shares Outstanding 26.4M Preferred Shares Outstanding 4.0M Market Cap $171.6M Warrants Outstanding a 14.3M Cash and Cash Equivalents $27.4M 2023 Q2 Cash Burn b $9.3M Current Price $6.52 Aver

  27. Slide 27: TriSalus: Focused on Innovative Approaches to Improving Outcomes for Patients with Liver and Pancreas Tumors

    27 TriSalus : Focused on Innovative Approaches to Improving Outcomes for Patients with Liver and Pancreas Tumors Medtech focused on growth and innovation Multiple value - creating opportunities anticipated over the next 18 months Targeting multiple high value markets, all characterized by high unmet

  28. Slide 28: Thank You!

    A TiSalus Thank You!

TriSalus Life Sciences — Investor Presentation (September 2023) on 6ix